FDA 483 - Takeda Manufacturing Singapore Pte. Ltd. - November 10, 2022
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Takeda Singapore Pte. Ltd., a licensed biological manufacturer, revealed significant deficiencies in their quality system. The firm failed to adequately investigate unexplained discrepancies and negative trends, often lacking identified root causes, immediate corrections, or proper CAPA initiation and justification. Additionally, the quality control unit's responsibilities and procedures were not fully followed, with inadequate training in Good Documentation Practices and data integrity leading to multiple instances of missing or inconsistent electronic data.
- Inspection Date
- November 10, 2022
- Product Type
- Biologics
ID · d827a37b-bbdf-48aa-868d-4eff30361421